ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)

BACKGROUND: There is a lack of treatment options for HGG and LGG patients. BRAFV600E mutations are uncommon in glioma, with a poor long-term prognosis. Combined BRAF/MEK inhibition extends progression-free survival (PFS) and overall survival (OS) in BRAF V600E–mutated melanoma, non small-cell lung c...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Wen, Patrick, Stein, Alexander, van den Bent, Martin, De Greve, Jacques, Dietrich, Sascha, De Vos, Filip, von Bubnoff, Nikolas, van Linde, Myra, Lai, Albert, Prager, Gerald, Campone, Mario, Fasolo, Angelica, Lopez-Martin, Jose, Min Kim, Tae, Mason, Warren, Hofheinz, Ralf-Dieter, Blay, Jean-Yves, Cho, Daniel, Gazzah, Anas, Gomez-Roca, Carlos, Yachnin, Jeffrey, Boran, Aislyn, Burgess, Paul, Palanichamy, Ilan, Gasal, Eduard, Subbiah, Vivek
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2019
Soggetti:
Adult Clinical Trials - Non-Immunologic
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847590/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.073
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi